Pivotal bioequivalence trial of ELI 200 vs branded formulation.

Trial Profile

Pivotal bioequivalence trial of ELI 200 vs branded formulation.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs ELI 200 (Primary) ; Opioid analgesics
  • Indications Pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors Elite Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2016 According to Elite Pharmaceuticals media release, the U.S. Food and Drug Administration (the "FDA") has issued a Complete Response Letter (the "CRL") regarding the New Drug Application (the "NDA") for SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride). The CRL determined that the NDA was not ready for approval in its present form.
    • 09 May 2016 According to an Elite Pharmaceuticals media release, the New Drug Application (NDA) for ELI-200 (SequestOX) has been accepted and granted priority review by the FDA with target action date under the Prescription Drug User Fee Act (PDUFA) of July 14, 2016.
    • 09 Feb 2016 Elite Pharmaceuticals has submitted a 505(b)(2) NDA to the US FDA, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top